KROS · Insider Trading
Keros Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by KROS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Annita Tanini | Corp. Controller & VP, Finance | Sell | −1,224 | −$12.59K |
| 2026-08-20 | Charles W. Newton | Director | Sell | −551 | −$5.68K |
| 2026-08-20 | Lorena Raquel Lerner | Chief Scientific Officer | Sell | −3,568 | −$36.71K |
| 2026-08-20 | Esther Cho | Chief Legal Officer | Sell | −4,485 | −$46.15K |
| 2026-08-19 | Jean Jacques Bienaime | Director | Buy | +1,000 | +$10.27K |
| 2026-07-17 | Jean Jacques Bienaime | Director | Buy | +1,000 | +$10.61K |
| 2026-07-06 | Anne Prener | Director | A | +13,786 | — |
| 2026-06-17 | Jean Jacques Bienaime | Director | Buy | +1,000 | +$10.19K |
| 2026-06-15 | Charles W. Newton | Director | Sell | −550 | −$5.52K |
| 2026-06-08 | Nima Farzan | Director | Sell | −2,625 | −$28.17K |
| 2026-06-08 | Julius Knowles | Director | Sell | −2,625 | −$28.17K |
| 2026-06-05 | Jean Jacques Bienaime | Director | A | +7,142 | — |
| 2026-06-05 | Alpna Seth | Director | A | +7,142 | — |
| 2026-06-05 | Mary Ann Gray | Director | A | +7,142 | — |
| 2026-06-05 | Nima Farzan | Director | A | +7,142 | — |
| 2026-06-05 | Julius Knowles | Director | A | +7,142 | — |
| 2026-06-05 | Alpna Seth | Director | Sell | −2,625 | −$28.14K |
| 2026-05-19 | Jean Jacques Bienaime | Director | Buy | +1,000 | +$10.58K |
| 2026-04-17 | Jean Jacques Bienaime | Director | Buy | +1,000 | +$11.70K |
| 2026-04-06 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | M | +55,000 | +$16.50K |
| 2026-03-27 | Esther Cho | Chief Legal Officer | A | +80,000 deriv. | — |
| 2026-03-11 | Jean Jacques Bienaime | Director | Buy | +2,000 | +$22.42K |
| 2026-03-11 | Charles W. Newton | Director | A | +13,215 | — |
| 2026-02-26 | Lorena Raquel Lerner | Chief Scientific Officer | A | +75,000 deriv. | — |
| 2026-02-26 | Esther Cho | Chief Legal Officer | A | +80,000 deriv. | — |
| 2026-02-26 | Keith Regnante | CHIEF FINANCIAL OFFICER | A | +60,000 deriv. | — |
| 2026-02-26 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | A | +317,000 deriv. | — |
| 2026-02-20 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | Sell | −7,015 | −$113.43K |
| 2026-02-20 | Keith Regnante | CHIEF FINANCIAL OFFICER | Sell | −4,739 | −$77.48K |
| 2026-02-20 | Lorena Raquel Lerner | Chief Science Officer | Sell | −3,873 | −$63.32K |
| 2026-02-20 | Esther Cho | SVP, General Counsel | Sell | −4,745 | −$77.58K |
| 2026-01-09 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | A | +62,500 deriv. | — |
| 2025-12-18 | Julius Knowles | Director | D | −322,021 | −$5.72M |
| 2025-12-18 | Carl L Gordon | Director | D | −214,522 | −$3.81M |
| 2025-12-18 | OrbiMed Capital GP VII LLC | Director | D | −643,566 | −$11.42M |
| 2025-10-17 | Pontifax (Cayman) IV L.P. | 10%+ Owner | Sell | −38,298,648 | −$679.80M |
| 2025-10-15 | Daniel Schneeberger | 10%+ Owner | Sell | −21,557,056 | −$382.64M |
| 2025-09-05 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | A | +90,500 | — |
| 2025-06-24 | Daniel Schneeberger | 10%+ Owner | X | −6,800 | −$472.00K |
| 2025-06-12 | ADAR1 Capital Management GP, LLC | 10%+ Owner | E | −5,256 deriv. | — |
| 2025-06-11 | Tomer Kariv | Director | — | — | — |
| 2025-06-11 | Ran Nussbaum | Director | — | — | — |
| 2025-06-06 | Alpna Seth | Director | A | +5,250 | — |
| 2025-06-06 | Jean Jacques Bienaime | Director | A | +5,250 | — |
| 2025-06-06 | Ran Nussbaum | Director | A | +5,250 | — |
| 2025-06-06 | Nima Farzan | Director | A | +5,250 | — |
| 2025-06-06 | Julius Knowles | Director | A | +5,250 | — |
| 2025-06-06 | Carl L Gordon | Director | A | +5,250 | — |
| 2025-06-06 | Mary Ann Gray | Director | A | +5,250 | — |
| 2025-06-06 | Tomer Kariv | Director | A | +5,250 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Carl L Gordon | Director | 764,405 | $8.66M |
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER | 440,708 | $4.99M |
| Tomer Kariv | Director | 160,512 | $1.82M |
| Ran Nussbaum | Director | 160,512 | $1.82M |
| Julius Knowles | Director | 113,191 | $1.28M |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | $679.80K |
| Annita Tanini | Corp. Controller & VP, Finance | 45,144 | $511.48K |
| OrbiMed Capital GP VII LLC | Director | 45,057 | $510.50K |
| Yung H. Chyung | Chief Medical Officer | 44,000 | $498.52K |
| Keith Regnante | CHIEF FINANCIAL OFFICER | 39,261 | $444.83K |
| Esther Cho | Chief Legal Officer | 35,770 | $405.27K |
| Lorena Raquel Lerner | Chief Scientific Officer | 27,559 | $312.24K |
| Jean Jacques Bienaime | Director | 19,592 | $221.98K |
| Anne Prener | Director | 13,786 | $156.20K |
| Mary Ann Gray | Director | 12,392 | $140.40K |
| Charles W. Newton | Director | 12,114 | $137.25K |
| Alpna Seth | Director | 9,767 | $110.66K |
| Nima Farzan | Director | 9,767 | $110.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KROS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.